Arabic Arabic English English French French German German
dark

Adagio Makes Case for Anti-COVID-19 Antibody Based on New Data

Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Yorkshire and Humber AHSN showcase innovations to senior NHS figures

Next Post

Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)

Related Posts
Total
0
Share